<DOC>
	<DOCNO>NCT02749656</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 0.25 % Desoximetasone cream ( Topoxy® ) compare 0.25 % Desoximetasone cream ( Topicorte® ) treatment scalp psoriasis .</brief_summary>
	<brief_title>Efficacy Safety 0.25 % Desoximetasone Cream ( Topoxy® ) Treatment Scalp Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Desoximetasone</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Diagnosed scalp psoriasis dermatologist 3 . Has scalp psoriasis Involve ≥ 10 % total scalp area also clinical sign , previous diagnosis , psoriasis trunk and/or limbs 4 . Total severity scalp psoriasis grade mild severe accord Investigator 's Global Assessment score ( IGA ) 5 . Clinical sign ( redness , thickness , scaliness ) score `` Moderate '' least 1 sign `` slight '' two sign 6 . All participant agree participate study already complete sign consent form 1 . Treated medication include study Topical corticosteroid scalp psoriasis ( except emollient shampoo ) within 2 week Very potent topical corticosteroid psoriasis area Narrow band Ultraviolet B ( NBUVB ) within 2 week Oral psoralen plus Ultraviolet A ( PUVA ) oral medication ( Methotrexate , Acitretin , Cyclosporine ) within 4 week Biologic agent concomitant medication could affect scalp psoriasis ( Beta blocker , Antimalarial drug , Lithium ) within 6 month 2 . Has skin infection atrophic skin scalp 3 . Has history allergic reaction hypersensitivity 0.25 % Desoximetasone 4 . Female participant pregnancy lactation period 5 . Participants unable come followup visit hospital 6 . Participants underlie disease e.g . diabetes mellitus , hypertension , thyroid disease 7 . Vulnerable subject e.g . illiterate person</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Scalp psoriasis</keyword>
	<keyword>0.25 % Desoximetasone cream</keyword>
</DOC>